Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian Mother Threatens Class-Action Against TGA Over Zoloft

This article was originally published in PharmAsia News

Executive Summary

The mother of an Australian girl alleged to have become suicidal after taking Pfizer's Zoloft (sertraline) is considering a suit against the country's drug regulator. The mother settled her $59,000 suit against the physician who prescribed the drug. She said she was contemplating a class-action suit against the Therapeutic Goods Administration on grounds it did not advise the public anti-depressant drugs have risks. The suit against the doctor alleged he falsely promoted Zoloft, the daughter attempted suicide, and the mother had to quit her job to care for the 16 year old. It was discovered the girl had a genetic defect that caused her to have adverse reactions to the sertraline. (Click here for more

You may also be interested in...

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

BioNTech Looks To AI Partnership To Accelerate Drug Discovery

The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.

Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts